Evidence map›Paper›PMID 33421974›Full record

ArticleCancer research and treatment2021

Correlation of NUF2 Overexpression with Poorer Patient Survival in Multiple Cancers.

Xiaodan Jiang, Yan Jiang, Senbiao Luo, Karthik Sekar, Clara Kai Ting Koh, Amudha Deivasigamani, Qingzhe Dong, Niankai Zhang, Shenling Li, Fengyun Hao and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Frontiers in oncology · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Xiaodan JiangDepartment of Otorhinolaryngology-Head and Neck Surgery, Key Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
Yan JiangDepartment of Otorhinolaryngology-Head and Neck Surgery, Key Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
Senbiao LuoDepartment of Oncological Surgery, Zhejiang Shangyu People's Hospital, Shaoxing, China.
Karthik SekarDivision of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore.
Clara Kai Ting KohDivision of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore.
Amudha DeivasigamaniDivision of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore.
Qingzhe DongDepartment of Biological Specimen Bank, The Affiliated Hospital of Qingdao University, Qingdao, China.
Niankai ZhangDepartment of Otorhinolaryngology-Head and Neck Surgery, Key Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
Shenling LiDepartment of Otorhinolaryngology-Head and Neck Surgery, Key Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
Fengyun HaoDepartment of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Brian Kim Poh GohDepartment of Hepato-Pancreato-Biliary Surgery, Singapore General Hospital, Singapore.
London Lucien OoiDepartment of Hepato-Pancreato-Biliary Surgery, Singapore General Hospital, Singapore.
Yu WangDivision of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore.
Kam Man HuiDivision of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore.
National Cancer Centre Singapore · SGAffiliated Hospital of Qingdao University · CNQingdao University · CNSingapore General Hospital · SGInstitute of Molecular and Cell Biology · SGShaoxing People's Hospital · CN

Funding

National Cancer CenterNational Medical Research Council NMRC/BNIG/2037/2015National Medical Research Council NMRC/OFYIRG/0076/2018SingHealth ONCO-ACP NCCRF-OACPCCS-YR2015-Aug-1
6 · The paper itself

Abstract

purposeNUF2 has been implicated in multiple cancers recently, suggesting NUF2 may play a role in the common tumorigenesis process. In this study, we aim to perform comprehensive meta-analysis of NUF2 expression in the cancer types included in the Cancer Genome Atlas (TCGA). MATERIALS AND

methodsRNA-sequencing data in 31 cancer types in the TCGA data and 11 independent datasets were used to examine NUF2 expression. Silencing NUF2 using targeting shRNAs in hepatocellular carcinoma (HCC) cell lines was used to evaluate NUF2's role in HCC in vitro and in vivo.

resultsNUF2 up-regulation is significantly observed in 23 out of the 31 cancer types in the TCGA datasets and validated in 13 major cancer types using 11 independent datasets. NUF2 overexpression was clinically important as high NUF2 was significantly associated with tumor stages in eight different cancers. High NUF2 was also associated with significantly poorer patient overall survival and disease-free survival in eight and six cancers, respectively. We proceeded to validate NUF2 overexpression and its negative association with overall survival at the protein level in an independent cohort of 40 HCC patients. Compared to the non-targeting controls, NUF2 knockdown cells showed significantly reduced ability to grow, migrate into a scratch wound and invade the 8 μm porous membrane in vitro. Moreover, NUF2 knockdown cells also formed significantly smaller tumors than control cells in mouse xenograft assays in vivo.

conclusionNUF2 up-regulation is a common feature of many cancers. The prognostic potential and functional impact of NUF2 up-regulation warrant further studies.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsApoptosisBiomarkers, TumorCell Cycle ProteinsCell ProliferationFemaleHumansMaleMiceMice, NudeMiddle AgedNeoplasmsPrognosisSurvival RateTumor Cells, CulturedBiomarkers, TumorCell Cycle ProteinsNUF2 protein, humanCell cycleDisease-free survivalNUF2Overall survivalPan-cancer

Identifiers

PMID33421974
PMCPMC8524009
OpenAlexW3120205217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.